-
Je něco špatně v tomto záznamu ?
Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration
LM. Ørnbjerg, CH. Brahe, J. Askling, A. Ciurea, H. Mann, F. Onen, EK. Kristianslund, D. Nordström, MJ. Santos, C. Codreanu, J. Gómez-Reino, Z. Rotar, B. Gudbjornsson, D. Di Giuseppe, MJ. Nissen, K. Pavelka, M. Birlik, T. Kvien, KK. Eklund, A....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 1939-01-01 do 2024-12-31
Health & Medicine (ProQuest)
od 1939-01-01 do 2024-12-31
Family Health Database (ProQuest)
od 1939-01-01 do 2024-12-31
ROAD: Directory of Open Access Scholarly Resources
- MeSH
- adherence k farmakoterapii statistika a číselné údaje MeSH
- biologické přípravky terapeutické užití MeSH
- databáze faktografické MeSH
- dospělí MeSH
- inhibitory TNF terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- registrace MeSH
- spondylartritida farmakoterapie MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
OBJECTIVE: To study drug retention and response rates in patients with axial spondyloarthritis (axSpA) initiating a first tumour necrosis factor inhibitor (TNFi). METHODS: Data from 12 European registries, prospectively collected in routine care, were pooled. TNFi retention rates (Kaplan-Meier statistics), Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive disease (<1.3), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <40 mm and Assessment of SpondyloArthritis International Society responses (ASAS 20/40) were assessed at 6, 12 and 24 months. RESULTS: A first TNFi was initiated in 24 195 axSpA patients. Heterogeneity of baseline characteristics between registries was observed. Twelve-month retention was 80% (95% CI 79% to 80%), ranging from 71% to 94% across registries. At 6 months, ASDAS Inactive disease/BASDAI<40 rates were 33%/72% (LUNDEX-adjusted: 27%/59%), ASAS 20/40 response rates 64%/49% (LUNDEX-adjusted 52%/40%). In patients initiating first TNFi after 2009, 6097 patients was registered to fulfil ASAS criteria for axSpA, 2935 was registered to fulfil modified New York Criteria for Ankylosing Spondylitis and 1178 patients was registered as having non-radiographic axSpA. In nr-axSpA patients, we observed lower 12-month retention rates (73% (70%-76%)) and lower 6-month LUNDEX adjusted response rates (ASDAS Inactive disease/BASDAI40 20%/50%, ASAS 20/40 45%/33%). For patients initiating first TNFi after 2014, 12-month retention rate, but not 6-month response rate, was numerically higher compared with patients initiating TNFi in 2009-2014. CONCLUSION: A large European database of patients with axSpA initiating a first TNFi treatment in routine care, demonstrated that 27% of patients achieved ASDAS inactive disease after 6 months, while 59% achieved BASDAI <40. Four of five patients continued treatment after 1 year.
biorx si and the Department of Rheumatology University Medical Centre Ljubljana Ljubljana Slovenia
Clinical Epidemiology Division Department of Medicine Solna Karolinska Institutet Stockholm Sweden
Department of Rheumatology Geneva University Hospital Geneva Switzerland
Department of Rheumatology University Hospital of Iceland Reykjavik Iceland
Department of Rheumatology Zurich University Hospital Zurich Switzerland
GISEA Registry Rheumatology Unit DETO University of Bari Bari Italy
Inflammation Center Department of Rheumatology Helsinki University Hospital Helsinki Finland
NOR DMARD Registry Department of Rheumatology Diakonhjemmet Hospital Oslo Norway
Research Unit Spanish Society of Rheumatology Madrid Spain
ROB FIN Registry Helsinki University and Helsinki University Hospital Helsinki Finland
TURKBIO Registry Division of Rheumatology School of Medicine Dokuz Eylul University Izmir Turkey
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023509
- 003
- CZ-PrNML
- 005
- 20201214130230.0
- 007
- ta
- 008
- 201125s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/annrheumdis-2019-215427 $2 doi
- 035 __
- $a (PubMed)31431486
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Ørnbjerg, Lykke Midtbøll $u EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark. DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.
- 245 10
- $a Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration / $c LM. Ørnbjerg, CH. Brahe, J. Askling, A. Ciurea, H. Mann, F. Onen, EK. Kristianslund, D. Nordström, MJ. Santos, C. Codreanu, J. Gómez-Reino, Z. Rotar, B. Gudbjornsson, D. Di Giuseppe, MJ. Nissen, K. Pavelka, M. Birlik, T. Kvien, KK. Eklund, A. Barcelos, R. Ionescu, C. Sanchez-Piedra, M. Tomsic, ÁJ. Geirsson, AG. Loft, I. van der Horst-Bruinsma, G. Jones, F. Iannone, L. Hyldstrup, NS. Krogh, ML. Hetland, M. Østergaard,
- 520 9_
- $a OBJECTIVE: To study drug retention and response rates in patients with axial spondyloarthritis (axSpA) initiating a first tumour necrosis factor inhibitor (TNFi). METHODS: Data from 12 European registries, prospectively collected in routine care, were pooled. TNFi retention rates (Kaplan-Meier statistics), Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive disease (<1.3), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <40 mm and Assessment of SpondyloArthritis International Society responses (ASAS 20/40) were assessed at 6, 12 and 24 months. RESULTS: A first TNFi was initiated in 24 195 axSpA patients. Heterogeneity of baseline characteristics between registries was observed. Twelve-month retention was 80% (95% CI 79% to 80%), ranging from 71% to 94% across registries. At 6 months, ASDAS Inactive disease/BASDAI<40 rates were 33%/72% (LUNDEX-adjusted: 27%/59%), ASAS 20/40 response rates 64%/49% (LUNDEX-adjusted 52%/40%). In patients initiating first TNFi after 2009, 6097 patients was registered to fulfil ASAS criteria for axSpA, 2935 was registered to fulfil modified New York Criteria for Ankylosing Spondylitis and 1178 patients was registered as having non-radiographic axSpA. In nr-axSpA patients, we observed lower 12-month retention rates (73% (70%-76%)) and lower 6-month LUNDEX adjusted response rates (ASDAS Inactive disease/BASDAI40 20%/50%, ASAS 20/40 45%/33%). For patients initiating first TNFi after 2014, 12-month retention rate, but not 6-month response rate, was numerically higher compared with patients initiating TNFi in 2009-2014. CONCLUSION: A large European database of patients with axSpA initiating a first TNFi treatment in routine care, demonstrated that 27% of patients achieved ASDAS inactive disease after 6 months, while 59% achieved BASDAI <40. Four of five patients continued treatment after 1 year.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a biologické přípravky $x terapeutické užití $7 D001688
- 650 _2
- $a databáze faktografické $7 D016208
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a adherence k farmakoterapii $x statistika a číselné údaje $7 D055118
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a spondylartritida $x farmakoterapie $7 D025241
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a inhibitory TNF $x terapeutické užití $7 D000079424
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Brahe, Cecilie Heegaard $u EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark cecilie.cornelia.heegaard.brahe@regionh.dk. DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.
- 700 1_
- $a Askling, Johan $u Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Ciurea, Adrian $u Department of Rheumatology, Zurich University Hospital, Zurich, Switzerland.
- 700 1_
- $a Mann, Herman $u Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Onen, Fatos $u TURKBIO Registry, Division of Rheumatology, School of Medicine Dokuz Eylul University, Izmir, Turkey.
- 700 1_
- $a Kristianslund, Eirik Klami $u NOR-DMARD Registry, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
- 700 1_
- $a Nordström, Dan $u ROB-FIN Registry, Helsinki University and Helsinki University Hospital, Helsinki, Finland.
- 700 1_
- $a Santos, Maria Jose $u Reuma.pt registry and Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
- 700 1_
- $a Codreanu, Catalin $u Department of Rheumatology, RRBR Registry and University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania.
- 700 1_
- $a Gómez-Reino, Juan $u Research Unit, Spanish Society of Rheumatology, Madrid, Spain.
- 700 1_
- $a Rotar, Ziga $u biorx.si and the Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
- 700 1_
- $a Gudbjornsson, Bjorn $u Centre for Rheumatology Research (ICEBIO), University Hospital and Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
- 700 1_
- $a Di Giuseppe, Daniela $u Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Nissen, Michael J $u Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland.
- 700 1_
- $a Pavelka, Karel $u Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Birlik, Merih $u TURKBIO Registry, Division of Rheumatology, School of Medicine Dokuz Eylul University, Izmir, Turkey.
- 700 1_
- $a Kvien, Tore $u NOR-DMARD Registry, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
- 700 1_
- $a Eklund, Kari Kalervo $u Inflammation Center, Department of Rheumatology, Helsinki University Hospital, Helsinki, Finland.
- 700 1_
- $a Barcelos, Anabela $u Rheuma.pt registry, Rheumatology Department - Centro Hospitalar do Baixo Vouga and Ibimed, Institute for Biomedicine, University of Aveiro, Aveiro, Portugal.
- 700 1_
- $a Ionescu, Ruxandra $u Department of Rheumatology, RRBR Registry and University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania.
- 700 1_
- $a Sanchez-Piedra, Carlos $u Research Unit, Spanish Society of Rheumatology, Madrid, Spain.
- 700 1_
- $a Tomsic, Matija $u biorx.si and the Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
- 700 1_
- $a Geirsson, Árni Jón $u Department of Rheumatology, University Hospital of Iceland, Reykjavik, Iceland.
- 700 1_
- $a Loft, Anne Gitte $u DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.
- 700 1_
- $a van der Horst-Bruinsma, Irene $u Amsterdam UMC, Department of Rheumatology, VU University Medical Centre Amsterdam, Amsterdam, The Netherlands.
- 700 1_
- $a Jones, Gareth $u Epidemiology Group, School of Medicine, Medical Science and Nutrition, University of Aberdeen, Aberdeen, UK.
- 700 1_
- $a Iannone, Florenzo $u GISEA Registry, Rheumatology Unit - DETO, University of Bari, Bari, Italy.
- 700 1_
- $a Hyldstrup, Lise $u EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.
- 700 1_
- $a Krogh, Niels Steen $u Zitelabs Aps, Copenhagen, Denmark.
- 700 1_
- $a Hetland, Merete Lund $u EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- 700 1_
- $a Østergaard, Mikkel $u EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- 773 0_
- $w MED00000444 $t Annals of the rheumatic diseases $x 1468-2060 $g Roč. 78, č. 11 (2019), s. 1536-1544
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31431486 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214130229 $b ABA008
- 999 __
- $a ok $b bmc $g 1595828 $s 1114185
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 78 $c 11 $d 1536-1544 $e 20190820 $i 1468-2060 $m Annals of the rheumatic diseases $n Ann Rheum Dis $x MED00000444
- LZP __
- $a Pubmed-20201125
